All In Biotech

BLA 125166 · Alexion Pharm

Soliris

Eculizumab · Iv (Infusion) · Complement Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Mar 16, 2007

Approved uses

6

Original approval plus efficacy supplements

Registered trials

119

51 Phase 3, 11 recruiting

FAERS reports

54,400

32,660 serious, 5,696 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS SOLIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of SOLIRIS, unless the risks of delaying therapy with SOLIRIS outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional...

What it is approved for

From the label in effect Jul 8, 2026.

SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.4 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (aHUS) SOLIRIS is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). 1.3 Generalized Myasthenia Gravis (gMG) SOLIRIS is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive. 1.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) SOLIRIS is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Mechanism: Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. SOLIRIS inhibits terminal complement-mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS. The precise mechanism by which eculizumab exerts its therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of terminal complement complex...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2025 Supplement 448 · Efficacy · priority review OrphanLabelLetter
  • Jun 27, 2019 Supplement 431 · Efficacy · priority review OrphanLabelLetterReview
  • Oct 23, 2017 Supplement 422 · Efficacy OrphanLabelLetterReview
  • Apr 30, 2014 Supplement 368 · Efficacy OrphanLetterLabel
  • Sep 23, 2011 Supplement 172 · Efficacy · priority review OrphanReviewLabel
  • Mar 16, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewOther
1 products under this application
  • SOLIRIS · ECULIZUMAB 300MG · INJECTABLE, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eculizumab" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,908
  • off label use4,826
  • haemoglobin decreased3,934
  • headache3,490
  • death2,768
  • pyrexia2,435
  • dyspnoea2,196
  • asthenia2,045
  • nausea1,999
  • drug ineffective1,967
  • haemolysis1,876
  • platelet count decreased1,838

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20074
200810
20091,259
2010801
20111,550
20121,359
20131,451
20145,560
20152,869
20165,450
20175,589
20186,298
20196,652
20202,347
20212,051
20222,081
20232,750
20242,744
20252,009
20261,566

Recalls

2 FDA enforcement reports for this application.

  • Jun 2, 2014 · Class I · Terminated

    Presence of Particulate Matter: Product failed the appearance for the presence of visible particles under labeled storage condition.

  • Nov 4, 2013 · Class I · Terminated

    Presence of Particulate Matter: Failed the appearance test for the presence of visible particles.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Soliris (Eculizumab)

2024 spending

$196M

Beneficiaries

419

4,569 claims

Per beneficiary

$468,242

$217.08 per unit

View as table
YearSpending
2020$210,563,942
2021$245,754,920
2022$266,299,811
2023$223,473,529
2024$196,193,579

Part B: Soliris (Eculizumab) · HCPCS J1300

2024 spending

$337M

Beneficiaries

956

12,215 claims

Per beneficiary

$352,952

2024 ASP limit $225.37 per unit

View as table
YearSpending
2020$610,453,125
2021$642,451,166
2022$616,117,828
2023$416,257,912
2024$337,421,792

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 208 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.